Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
AQST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.24 - $5.80
Previous CloseN/A
Volume606.88K
Average Volume (3M)1.40M
Market Cap
$283.76M
Enterprise Value$495.13M
Total Cash (Recent Filing)-$9.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 06, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding98,871,370
10 Day Avg. Volume1,452,320
30 Day Avg. Volume1,404,213
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.51
Price to Cash Flow (P/CF)-12.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.48
Enterprise Value/Ebitda-17.68
Forecast
1Y Price Target
$8.15Price Target Upside200.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Aquestive Therapeutics News
PremiumCompany Announcements
Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA
PremiumCompany Announcements
Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Aquestive Therapeutics Advances Product Pipeline and Market Access---
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsAnaphylm was safe and well-tolerated in the pediatric study with no serious adverse events.
FDA Approval ProcessFDA acceptance of the Anaphylm NDA submission is expected, and the advisory committee meeting process could highlight the potential benefits of Anaphylm for patients.
Market PotentialThe T1A market should be large enough for multiple no-needle epi players including Anaphylm, and no-needle epi products should ultimately 'grow the pie' and drive meaningful expansion of the T1A market beyond current autoinjectors longer-term.
Bears Say
Financial ConcernsAquestive ended with approximately $93M in cash and cash equivalents, which management expects should provide financial runway into 2026.
Regulatory ChallengesAnaphylm NDA submitted, setting up potential approval in early 2026.
---
Ownership Overview
14.54% Insiders
7.21% Mutual Funds
19.65% Other Institutional Investors
51.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $2.24 and its highest was $5.80 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Aquestive Therapeutics’s market cap is $283.76M.
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is May 06, 2025 which is in 30 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Mar 05, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.133 by -$0.057.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 98,871,370 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.133. Following the earnings report the stock price went down -7.527%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Currently, no hedge funds are holding shares in AQST
---
Aquestive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.15 (200.74% Upside)
$8.15 (200.74% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 449.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $213.8 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.85%
12-Months-Change
Fundamentals
Return on Equity
77.48%
Trailing 12-Months
Asset Growth
76.64%
Trailing 12-Months
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
---
AQST Company Deck
---
AQST Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Aquestive Therapeutics demonstrated significant progress in advancing its lead asset Anaphylm towards FDA approval and preparing for international expansion. However, challenges include decreased quarterly revenue, increased net loss, and legal setbacks for Libervant. The sentiment is mixed with balanced highlights and lowlights.Read More>---
AQST Stock 12 Month Forecast
Average Price Target
$8.15
▲(200.74% Upside)
Technical Analysis
Best Analysts Covering AQST
1 Year
1 Year Success Rate
18/36 ratings generated profit
1 Year Average Return
+40.06%
reiterated a buy rating 6 days ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +40.06% per trade.
---